

Amendments to the Claims

Claims 1-12 (cancelled)

¹
~~13.~~ (currently amended) A method of treating a patient suffering from or susceptible to Varicella Zoster virus infection, comprising administering to a patient a pharmaceutical composition comprising an isolated Varicella Zoster Virus IE63 protein ~~or a fragment or derivative thereof~~ and a pharmaceutically acceptable excipient, wherein the composition induces ~~an immunoprotective~~ a humoral or cellular immune response without significant, adverse side effects.

²
01 ~~14.~~ (currently amended) A method of treating a patient suffering from or susceptible to Varicella Zoster virus infection, comprising administering to a patient a pharmaceutical composition comprising an isolated nucleic acid encoding IE63 ~~or a fragment or derivative thereof~~, wherein the composition induces ~~an immunoprotective~~ a humoral or cellular immune response without significant, adverse side effects.

³
~~15.~~ (previously added) A method of treating a patient suffering from or susceptible to Varicella Zoster virus infection as claimed in claim ¹~~13~~, additionally comprising other VZV antigens.

⁴
4 ~~16.~~ (currently amended) A method of treating a patient suffering from or susceptible to Varicella Zoster virus infection as claimed in claim ³~~15~~, wherein the other VZV antigens are selected from the group, gpl, gpII, gpIII, gpIV, gpV or IE62 or immunological functional derivative anchorless derivatives thereof.

⁵
~~17.~~ (previously added) A method of treating a patient suffering from or susceptible to Varicella Zoster virus infection as claimed in claim ¹~~13~~, additionally comprising an adjuvant.

⁶
~~18.~~ (previously added) A method of treating a patient suffering from or susceptible to Varicella Zoster virus infection as claimed in claim ⁵~~17~~, wherein the adjuvant preferentially induces a TH1 response.

D

⁷~~19~~ (previously added) A method of treating a patient suffering from or susceptible to Varicella Zoster virus infection as claimed in claim ~~18~~⁶, wherein the antigen is presented as an oil in water emulsion together with QS21 and 3D-MPL.

⁸
⁰¹ ~~20~~ (currently amended) A method of producing a pharmaceutical composition comprising an isolated Varicella Zoster virus IE63 protein ~~or fragment or derivative thereof~~, or an isolated nucleic acid encoding a Varicella Zoster virus IE63 protein ~~or fragment or derivative thereof~~, comprising mixing said protein ~~or fragment or derivative thereof~~ or said nucleic acid with a pharmaceutically acceptable excipient.

⁹ ~~21~~ (previously added) A method as claimed in claim ~~20~~⁸, wherein the excipient comprises an adjuvant.
